Neuroblastoma is a rare and aggressive type of cancer that affects young children. It originates from the neuroblasts or immature nerve cells present in the fetal or embryonic stage. The disease develops from the nerve tissues found in various parts of the body, including the neck, chest, abdomen, and pelvis. Although rare, neuroblastoma is the most common cancer in infants and the third most common pediatric cancer. The current treatment options for neuroblastoma include surgery, chemotherapy, radiation therapy, and immunotherapy. However, due to the high relapse rate, there is a need for new and effective treatment options. This article provides an overview of the neuroblastoma pipeline products market segmentation by targets.

Overview of Neuroblastoma Pipeline Products

Neuroblastoma pipeline products refer to the drugs and therapies under development for the treatment of neuroblastoma. These products are in various stages of clinical trials, and some have shown promising results. The primary aim of these products is to improve the survival rates and reduce the side effects associated with the current treatment options. The neuroblastoma pipeline products market is expected to grow significantly in the coming years, driven by the increasing prevalence of the disease and the need for better treatment options.

Neuroblastoma Pipeline Products Market Segmentation by Targets

The neuroblastoma pipeline products can be segmented based on the targets they act on. The targets are the specific molecules or proteins that the drugs or therapies interact with to produce a therapeutic effect. The following are the major targets of neuroblastoma pipeline products.

1. Immunotherapies

Immunotherapies are a type of treatment that enhances the body's immune system to fight cancer cells. These therapies work by stimulating the immune system to recognize and attack cancer cells. The following are the major targets of immunotherapies in neuroblastoma pipeline products.

a. GD2

GD2 is a molecule that is present on the surface of neuroblastoma cells. Immunotherapies that target GD2 have shown promising results in clinical trials. These therapies include chimeric antigen receptor (CAR) T-cell therapy, bispecific T-cell engagers (BiTEs), and monoclonal antibodies.

b. CD171

CD171, also known as L1CAM, is a protein that is overexpressed in neuroblastoma cells. Immunotherapies that target CD171 have shown to be effective in preclinical studies.

2. Tyrosine Kinase Inhibitors

Tyrosine kinase inhibitors (TKIs) are a type of drug that blocks the action of specific enzymes called tyrosine kinases. These enzymes are involved in the growth and division of cancer cells. The following are the major targets of TKIs in neuroblastoma pipeline products.

a. ALK

Anaplastic lymphoma kinase (ALK) is a protein that is mutated in some neuroblastoma cases. TKIs that target ALK have shown to be effective in clinical trials.

b. RET

Rearranged during transfection (RET) is a protein that is overexpressed in some neuroblastoma cases. TKIs that target RET have shown to be effective in preclinical studies.

For more target insights into the Neuroblastoma pipeline products market, download a free report sample